[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 10, Issue 3 (Int J Mol Cell Med (In Press) 2021) ::
Int J Mol Cell Med 2021, 10(3): 0-0 Back to browse issues page
Metformin is a Novel Suppressor for Vimentin in Human Gastric Cancer Cell Line
Shiva Valaee1 , Mehdi Shamsara2 , Mohammad Mehdi Yaghoobi 3
1- Research Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.
2- Department of Animal Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
3- Research Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran. , m.yaghoobi@kgut.ac.ir
Abstract:   (389 Views)
Vimentin, an intermediate filament of mesenchymal cells, is upregulated in epithelial-mesenchymal transition (EMT) and has a main role in cancer metastasis. As a new strategy to control metastatic outgrowth, EMT markers are generally inhibited using some drugs or specific siRNA. In this study, AGS gastric cancer cells were treated with metformin and vimentin-specific siRNA (vim-siRNA) for 48 h. The impact of metformin and vim-siRNA on vimentin downregulation in AGS cells were analyzed by quantitative PCR and Western blot. Following treatment with metformin and vim-siRNA, cell motility, migration and invasion abilities of AGS cells were also analyzed. The results showed that inhibition of vimentin due to metformin was comparable with the vim-siRNA. Furthermore, wound-healing and invasion assays showed a significant decrease in migration and invasion of AGS cells following metformin and vim-siRNA treatment. Our finding for the first time indicated that metformin can be an alternative to specific siRNA for inhibition of vimentin expression and migration of AGS cell line. Taken together, our data indicates that the use of metformin might have a priority to siRNA for inhibition of gastric cancer cell behaviors siRNA is more unstable and expensive than metformin, and needs special vehicles and delivery strategies for efficient transfection of cells. Further in vivo studies can reveal metformin's potential in inhibition of EMT and metastasis of cancer cells.
Keywords: Gastric cancer, metformin, vimentin, epithelial-mesenchymal transition
Full-Text [PDF 357 kb]   (80 Downloads)    
Type of Study: Original Article | Subject: Cancer
Received: 2021/01/17 | Accepted: 2021/10/18 | Published: 2021/08/19
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Valaee S, Shamsara M, Yaghoobi M M. Metformin is a Novel Suppressor for Vimentin in Human Gastric Cancer Cell Line. Int J Mol Cell Med. 2021; 10 (3)
URL: http://ijmcmed.org/article-1-1552-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 3 (Int J Mol Cell Med (In Press) 2021) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.04 seconds with 29 queries by YEKTAWEB 4355